Korean J Pediatr.
2010 Mar;53(3):358-363. 10.3345/kjp.2010.53.3.358.
Effect of Synagis(R) (palivizumab) prophylaxis on readmission due to respiratory syncytial virus in very low birth weight infants
- Affiliations
-
- 1Department of Pediatrics, Samsung Medical Center, Seoul, Korea. wonspark@skku.edu
- 2Department of Pediatrics, Kosin University College of Medicine, Busan, Korea.
- 3Department of Pediatrics, Dong-A University College of Medicine, Busan, Korea.
- 4Department of Pediatrics, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
- 5Department of Pediatrics, Masan Samsung Hospital, Masan, Korea.
- 6Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Seoul, Korea.
- KMID: 2281317
- DOI: http://doi.org/10.3345/kjp.2010.53.3.358
Abstract
- PURPOSE
The aim of this study was to determine the efficacy of Synagis(R) (palivizumab) in reducing the respiratory syncytial virus (RSV) readmission rate in very low birth weight infants (VLBWI ) and the subgroup that showed the most effective vaccination.
METHODS
We enrolled 350 VLBWI who had been discharged alive from the neonatal intensive care unit of Samsung Medical Center from January 2005 to December 2007 and were followed up for at least one year. A retrospective study based on medical records was performed for a period of one year after discharge. RSV readmission rate was investigated according to BPD (bronchopulmonary dysplasia, requiring oxygen at postnatal day 28) and Synagis(R) prophylaxis. We categorized the subgroups by the severity of BPD gestational age, and birth weight and compared the RSV readmission rates between subgroups.
RESULTS
Eleven VLBWI were readmitted. Synagis(R) prophylaxis resulted in a 86% reduction in the rate of readmission due to RSV infection (prophylaxis group, 0.7% and no prophylaxis group, 5.0%; P=0.02). Readmission rate in BPD patients was also reduced in the prophylaxis group (0.7% in the prophylaxis group vs. 5.2% in the no prophylaxis group, P=0.03). The readmission rate in patients without BPD was reduced in the prophylaxis group (0% in the prophylaxis group vs. 4.9% in the no prophylaxis group, P=1.00), but this was not statistically significant.
CONCLUSION
Synagis(R) prophylaxis was effective at reducing RSV readmission in VLBWI. Its efficacy was verified irrespective of BPD, gestational age, or birth weight.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Analysis of Palivizumab Prophylaxis in Patients with Acute Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus
- Erratum: Effect of Prophylactic Palivizumab on Admission Due to Respiratory Syncytial Virus Infection in Former Very Low Birth Weight Infants with Bronchopulmonary Dysplasia
- Respiratory Syncytial Virus Related Readmission in Preterm Infants Less than 34 weeks' Gestation Following Discharge from a Neonatal Intensive Care Unit in Korea
- Outcomes of Palivizumab Prophylaxis for Respiratory Syncytial Virus Infection in Preterm Children with Bronchopulmonary Dysplasia at a Single Hospital in Korea from 2005 to 2009
- Seasonal Variations of Respiratory Syncytial Virus Infection among the Children under 60 Months of Age with Lower Respiratory Tract Infections in the Capital Area, the Republic of Korea, 2008-2011
